Celcuity's Gedatolisib Nears FDA Decision with Strong Phase 3 Data
Event summary
- FDA granted Priority Review for gedatolisib in HR+/HER2- PIK3CA WT advanced breast cancer with a PDUFA goal date of July 17, 2026.
- Phase 3 VIKTORIA-1 study showed median PFS of 16.6 months for gedatolisib triplet vs. 1.9 months for fulvestrant in PIK3CA WT cohort.
- Celcuity reported $177.0 million net loss for 2025, up from $111.8 million in 2024, with cash reserves expected to last through 2027.
- Topline results from PIK3CA mutant cohort of Phase 3 VIKTORIA-1 study expected in Q2 2026.
The big picture
Celcuity's progress with gedatolisib represents a significant step in the development of targeted therapies for advanced breast cancer. The FDA's Priority Review designation underscores the potential of this treatment, which has demonstrated superior progression-free survival compared to existing therapies. The company's financials reflect heavy investment in commercial readiness, positioning it for a potential market entry in a competitive oncology space.
What we're watching
- Regulatory Outcome
- Whether the FDA will approve gedatolisib by the July 2026 PDUFA date, potentially transforming treatment for HR+/HER2- advanced breast cancer.
- Commercial Readiness
- The pace at which Celcuity can scale commercial operations following potential approval, given significant increases in R&D and G&A expenses.
- Clinical Validation
- How the topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study will impact the broader adoption of gedatolisib.
Related topics